Skip to main content

Table 6 Median values and p-values between the 3 groups of increasing, stable or decreasing PSAV values

From: Artificial neural network (ANN) velocity better identifies benign prostatic hyperplasia but not prostate cancer compared with PSA velocity

 

Increasing PSAV

(>0.75 ng/mL/year)

Stable PSAV

(-0.75 to 0.75 ng/mL/year)

Decreasing PSAV

(< -0.75 ng/mL/year)

Parameter

PCa (n = 35)

BPH (n = 32)

p-value

PCa (n = 9)

BPH (n = 98)

p-value

PCa (n = 5)

BPH (n = 20)

p-value

Age (years)

65

68

0.15

68

68

0.86

72

68.5

0.92

tPSA (ng/mL)

11.7*

11.5*$

0.72

4.8§

4.96

0.96

6.2*

4.39

0.067

%fPSA (%)

9.6*§

14.1

0.001

15

17.4

0.49

21

16

0.13

Volume (mL)

35

46.5

0.066

33

45

0.1

55

57.5

0.89

  1. The p-value is given for the comparison between the respective PCa and BPH patients (Mann-Whitney U Test)
  2. *significantly different to the respective patients in the stable group (P < 0.05; Mann-Whitney U Test)
  3. §significantly different to the respective patients in the decreasing group (P < 0.05; Mann-Whitney U Test)
  4. The Kruskal-Wallis Test for the PCa patients between all 3 groups showed for tPSA (p = 0.0003) and %fPSA (p = 0.0008) significant differences but not for age (p = 0.26) or volume (p = 0.17).
  5. The Kruskal-Wallis Test for the BPH patients between all 3 groups showed for tPSA (p < 0.0001) significant differences but not for %fPSA (p = 0.4), age (p = 0.96) or volume (p = 0.44).
Back to article page

BMC Urology

ISSN: 1471-2490

Contact us